Tuesday, 19 Nov 2019

You are here

Top 16 Drugs in Rheumatology 2016

Using data compiled from annual reports, SEC filings, press releases, company websites, recently released sales figures show that in 2016, 11 of the top 16 rheumatology drugs demonstrated blockbuster sales (>$1 billion per annum).  Highlights from this report include:

  • TNF inhibitors – the big three TNFi (ADA, ETN, INF) lead the way with $33.7 billion in 2016.  Humira continued as the worldwide leader in sales $16.1 billion.  Sales of all 5 TNFi totaled $37.9 billion.  While Humira growth (15%) continues, Enbrel has flattened (2%) and Remicade has declined (-2%).
  • Greatest growth from 2015 to 2016 was Cosentyx (332% to $1.1 billion in 2016), Otezla (116% to $1 billion) and Xeljanz (77% to $927 million).
  • Greatest losses were seen for NSAID market, with -12% drop for Celebrex, -4% drop for Arcoxia (Cox-2 inhibitor sold outside the USA) and a -2% drop for aspirin.
  • Psoriatic arthritis therapeutic market was hot with substantial growth by Cosentyx (332%), Otezla (116%) and Stelara (31%), in addition to TNF inhibitor growth.

TOP 16 RHEUMATOLOGY DRUGS – 2016 SALES

 

Brand

Generic

2015 Sales*

2016 Sales*

Growth Rate

1

Humira

Adalimumab

14012

16078

15%

2

Enbrel

Etanercept

8697

8874

2%

3

Remicade

Infliximab

8791

8789

-2%

4

Rituxan

Rituximab

5584

5765

3%

5

Stelara

Ustekinumab

2474

3232

31%

6

Simponi

Golimumab

2133

2719

27%

7

Orencia

Abatacept

1957

.2368

21%

8

Actemra

Tocilizumab

1432

1697

19%

9

Cimzia

Certolizumab

1191

1438

21%

10

Cosentyx

Secukinumab

261

1128

332%

11

Otezla

Apremilast

472

1017

116%

12

Xeljanz

Tofacitinib

523

927

77%

13

Celebrex

Celcoxib

830

733

-12%

14

Aspirin

Aspirin

525

513

-2%

15

Arcoxia

Etoricoxib

471

450

-4%

16

Ilaris

Canakinumab

236

283

20%

* Worldwide sales expressed millions (USD)

Add new comment

More Like This

Mallinckrodt Receives SEC Subpoena

Reuters reports that Mallinckrodt Plc has received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).

ACR Responds to CY2020 Medicare Physician Fee Schedule Proposed Rule

Rheumatology leaders commend CMS for proposing E/M code changes and urge agency to make additional changes to final rule.d

Parenteral Out-Performs Oral Weekly Methotrexate

A systematic review in PLOS suggests that parenteral MTX therapy is more successful than oral MTX in achieving optimal disease activity control. 

ACR Survey Shows Half of Patients Cannot Afford Treatments

Americans living with rheumatic disease face significant healthcare challenges, according to a national patient survey released this week by the American College of Rheumatology. More than 1,500 U.S. adults living with rheumatic disease responded to the survey, which asked a range of questions related to healthcare access, affordability and lifestyle. Key findings include that even though 90 percent of respondents reported having health insurance coverage, nearly 60 percent said they had difficulty affording their medications or treatments in the past year.

Medical Use of Cannabis in 2019

JAMA has published an overview of cannabis and its medical uses. Although nearly 10% of cannabis users in the United States report using it for medicinal purposes, there is insufficient evidence to support the use of medical cannabis for most conditions for which its use is advocated or advised. Nevertheless, there is increase in favoring the public availability of cannabis, largely for the management of more than 50 medical conditions.